MANNKIND CORPORATION MNKD (NASDAQ)

(NEW YORK)Pharmaceutical giants Merck & Co., Bristol-Myers Squibb Co. and Novartis AG will be among the companies hoping to catch the attention of physicians at the American Diabetes Associa...READ MORE

(VALENCIA, Calif.)Biotechnology company MannKind Corp. said Monday its first-quarter loss narrowed on lower research and development costs. The company lost $71.4 million, or 70 cents per share, com...READ MORE

(NEW YORK) MannKind shares traded heavily after the drug development company halted efforts to find a partner to market its Technosphere inhaled insulin. "Given current market sentiment, we...READ MORE

(VALENCIA, Calif.) Biotechnology company MannKind Corp. said Thursday that it is suspending partnership discussions for its inhalable insulin drug candidate following Pfizer Inc.'s warning of a ...READ MORE

(NEW YORK) Shares of companies developing inhaled insulin products are plunging in Wednesday morning trading, after a Pfizer study linked Nektar Therapeutics' Exubera drug to lung cancer...READ MORE

(NEW YORK)The prospects for inhaled insulin suffered another damaging blow earlier this month after Eli Lilly & Co. ended its late-stage development program, citing a lack of confidence in t...READ MORE

Among the stock activity stories for Monday, March 10, from AP Financial News: NEW YORK (AP) _ Shares of MannKind Corp. fell Monday over concerns the biotechnology company may join...READ MORE